Although most narcolepsy cases are sporadic, there is still a strong genetic basis. The family members of an affected individual have a 20 – 40-fold increased risk of developing narcolepsy. There is a strong association between narcolepsy and the human leukocyte antigen HLA-DQB1, as 90-99% of people (99% of Caucasians) affected with narcolepsy and cataplexy have the HLA-DQB1*06:02 allele. Approximately 15% of unaffected Caucasians, and 15 – 25% of the unaffected worldwide population, also has this allele, so other factors must be involved.
Most people affected by narcolepsy also suffer from cataplexy. A deficiency in the neurotransmitter hypocretin (orexin) has been implicated in many of these patients. However, there has currently not been any highly penetrant hypocretin-gene mutations identified, unlike the animal models. This supports the hypothesis that narcolepsy in humans is an autoimmune disease and the hypocretin-producing cells are targeted by the immune system.
Further evidence that supports the auto-immunity hypothesis includes the identification of auto-antibodies close to narcolepsy disease onset, an increase in newly diagnosed cases after the 2009 H1N1 influenza vaccination and the discovery of associations with other immune-related genes.
Narcolepsy is likely to have an environmental component, which may include infections, trauma, hormonal changes, stress or immune system problems.
DNA Narcolepsy Test
Determine if your genes increase your risk of narcolepsy.
Web apps are available to users who have taken the test.
Already took the test? Sign in to access your results.